This article is more than 5 years old. Information may no longer be current.

Enrollment completed in Leber’s hereditary optic neuropathy trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Enrollment has been completed in a phase 3 clinical trial of a treatment for Leber’s hereditary optic neuropathy, according to a press release from GenSight Biologics.

The RESCUE randomized, double-masked, sham-controlled multicenter trial will evaluate a single intravitreal injection of GS010, designed to treat Leber’s hereditary optic neuropathy caused by a mutation in the ND4 gene, in 37 patients, the release said.

One of two parallel trials, RESCUE will study GS010’s effectiveness in patients with an onset of vision loss of less than 6 months. Its counterpart, REVERSE, which completed enrollment in February, will evaluate its use in those with an onset of vision loss of 7 to 12 months.

The company expects to report data from the studies in 2018, the release said.